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Obesity has been increasing in prevalence worldwide and the majority of patients with type 2 diabetes are either overweight or
obese. Diabetes management in this population has been diﬃcult since a number of antidiabetes agents are associated with weight
gain. The eﬀects of various antidiabetes agents and antiobesity agents on glycemic control and body weight will be reviewed.
Brieﬂy, sulfonylureas, thiazolidinediones, and insulin are associated with weight gain, whereas metformin and amylin analogs are
weight neutral or associated with modest weight loss. Dipeptidyl-peptidase-4 inhibitors are weight neutral, whereas glucagon-like
peptide-1 analogs are associated with weight loss. The eﬀect of orlistat and sibutramine in type 2 diabetes is also evaluated. The
treatment of diabetes should not only focus on glycemic control as its sole intention, but it should factor in the eﬀect of these
various agents on weight, as well, since obesity aggravates insulin resistance, beta cell failure, and cardiovascular risk.
1.Introduction
Obesity has been increasing in prevalence worldwide and is
strongly associated with the development of type 2 diabetes
[1]. Both obesity and diabetes are associated with an increase
in morbidity and mortality primarily from cardiovascular
disease.Currently,about86%ofpatientswithtype2diabetes
areeitheroverweightorobese[2].Obesity,particularlyintra-
abdominal obesity, induces insulin resistance in muscle and
liver that leads to glucose intolerance [3]. Consequently,
insulin resistance has long been targeted for diabetes control.
Additionally, progressive loss of pancreatic beta cell function
hallmarks the central defect in diabetes and is related to
loss of incretin stimulation, amylin production, and the
eﬀects of glucotoxicity and lipotoxicity [4]. Hence, medical
treatment of diabetes has collectively targeted these various
pathophysiological mechanisms.
Intensive lifestyle modiﬁcation with diet and exercise
to achieve weight loss of at least 5–10% has been shown
to improve glycemic control with improvements in insulin
sensitivity and beta cell function [5]. Intensive glucose
lowering of HbA1c levels to less than 7% is associated with
signiﬁcant reduction in microvascular complications [6].
However, as has been shown in a number of prospective
trials including the United Kingdom Prospective Diabetes
Study (UKPDS), intensive glucose control is associated
with a median weight gain of 3–3.5kg. A more recent
example of this eﬀect is illustrated by the Action to Control
Cardiovascular Risk in Diabetes (ACCORD) trial which
compared standard therapy (HbA1c 7–7.9%) with intensive
glucose control (<6%) in over 10,000 subjects [7]. More
patients in the intensive group had signiﬁcant weight gain
of >10kg (28% versus 14%). For every 1% decrease in
HbA1c, there was a corresponding weight gain of about 2kg
[8]. Thus, the eﬀect of antidiabetes agents on weight and
obesity status is an important consideration when treating
patients with diabetes since obesity, itself, aggravates insulin
resistance and cardiovascular risk.
A number of medications including sulfonylureas, thia-
zolidinediones, and insulin are associated with weight gain
particularly when used in combination, whereas metformin
and amylin analogs are weight neutral or associated with
modest weight loss. DPP4-inhibitors are weight neutral
whereas GLP-1 analogs are associated with weight loss
(Figure 1). The eﬀect of various antidiabetes medication
c l a s s e so ng l y c e m i cc o n t r o la n dw e i g h tw i l lb er e v i e w e dh e r e .
Based on a practice-based approach, a therapeutic strategy
that balances weight and glucose control for obese type 2
diabetic patients will be presented in Figure 2 that is distinct
from the conventional glucose lowering approach [9].2 Journal of Obesity
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Figure 1: Eﬀects of various antidiabetes agents on body weight.
2.AntidiabetesAgents Associatedwith
WeightGain
2.1. Sulfonylureas. T h es u l f o n y l u r e a s( S U s )h a v eb e e ne x t e n -
sively used in the treatment of type 2 diabetes and are asso-
ciated with weight gain. SUs stimulate pancreatic betacells
directly to secrete insulin independent of glucose concen-
trations. SUs, when used as monotherapy, are expected to
decrease HbA1c by 1-2% [10, 11]. In UKPDS, 3,867 newly
diagnosed patients with type 2 diabetes were randomized to
intensive treatment with sulfonylurea (chlorpropamide 100–
500mg or glibenclamide 2.5–20mg), insulin, or conven-
tional dietary management [6]. The median HbA1c of 7.0%
in the intensive group was signiﬁcantly lower compared with
the conventional treatment (7.9%) over the 10-year study
period. However, patients on the intensive treatment group
had greater weight gain (mean 2.9kg; P<. 001) than the
conventional group. Patients on glibenclamide gained 1.7kg
more than the conventional group whereas those on insulin
gained 4.0kg more.
To determine the eﬀects of SU when combined with
metformin, Garber et al. conducted a multicenter, double-
blind study in which 486 type 2 diabetes patients (mean
HbA1c ∼8.7%) were randomized to glyburide/metformin
therapy (1.25/250mg), glyburide (2.5mg), or metformin
(500mg) monotherapy with titration to maximum doses
for 16 weeks [12]. There was greater reduction in HbA1c
(−2.27%) in the glyburide/metformin group compared
with both glyburide (−1.90%) and metformin (−1.53%)
monotherapy (P = .0003). Patients on glyburide/metformin
treatment had a weight increase of 1.6kg compared with
2.0kg in the glyburide group (P = NS). In contrast,
patients on metformin had a weight loss of 1.1kg. Thus,
the combination of SU with metformin results in superior
glycemiccontrolwithlessweightgainthanSUmonotherapy.
2.2. Thiazolidinediones. Thiazolidinediones (TZDs) reduce
hyperglycemia primarily by improving insulin sensitivity in
adipose, skeletal muscle, and liver tissues. These compounds
may also have some favorable eﬀects to preserve beta cell
function and prevent diabetes development in patients at
high risk [13, 14]. TZDs are used as monotherapy or in
combination with metformin or SUs in type 2 diabetes. In
the Prospective Pioglitazone Clinical Trial in Macrovascular
Events (PROactive) Study, 5,238 patients (mean HbA1c
∼7.8%) were randomized to pioglitazone 15mg to 45mg
(n = 2,605) or placebo (n = 2,633) in addition to their
antidiabetes agents. Following the 34.5-month study period,
the pioglitazone group achieved a reduction in HbA1c of
0.8% compared with 0.3% in the placebo group despite the
addition of more antidiabetes agents in the placebo group
[15]. There was an associated weight gain of 3.6kg in the
pioglitazone group as compared to a 0.4kg weight loss in the
placebo group. Despite weight gain, pioglitazone improved
some secondary cardiovascular outcomes with regard to
composite of all-cause mortality, nonfatal myocardial infarc-
tion, and stroke with multiple eﬀects of lowering cholesterol
and blood pressure.
The Diabetes Outcome Progression Trial (ADOPT) was
done to evaluate rosiglitazone monotherapy on glycemic
control compared with metformin or glyburide monother-
apy. Patients (mean HbA1c ∼7.4%) were randomized to
receive maximum daily doses of rosiglitazone 8mg (n =
1,456), glyburide 15mg (n = 1,441), or metformin 2g (n =
1,454). At 4 years, 40% of patients in the rosiglitazone group
had HbA1c <7%, as compared with 36% in the metformin
group and 26% in the glyburide group [16]. Weight gain
was a major consistent ﬁnding with the use of TZDs. Over a
period of 5 years, treatment with rosiglitazone resulted in an
average weight gain of 4.8kg versus 1.6kg in the glyburide
group whereas patients on metformin had a decrease in
weight (−2.9kg). The weight gain associated with TZDs was
postulated to be due to an increase in subcutaneous fat as
a result of fat redistribution from visceral adipose tissues,
which is related to major improvements in insulin sensitivity
in hepatic and peripheral tissues [17].Journal of Obesity 3
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Figure 2: Practice-based approach for balancing weight loss and glycemic control (HbA1c <7%) in uncomplicated type 2 diabetes.
The use of TZDs and metformin as an insulin-sensitizing
strategy as compared to an insulin-providing strategy with
SUs and insulin employed in diabetic patients with coronary
artery disease enrolled in the BARI 2D trial had a greater
likelihood of achieving glycemic control with HbA1c <7%
(insulin-sensitizing 55% versus insulin-providing 40%).
Insulin-sensitizing therapy also was associated with less
weight gain and hypoglycemia compared with the insulin-
providing therapy [18].
The combination of TZDs with incretin agonists dis-
cussedbelowbalancesbothglycemicandweightcontrol.The
addition of exenatide 10μg twice daily to rosiglitazone 4mg
twice daily resulted in weight loss of 1.2kg compared with
weight gain of 1.5kg with rosiglitazone monotherapy. There
was also a greater reduction in HbA1c in the combination
therapy group (−1.3% versus −1%;P<. 05) [19].
2.3. Insulin. By way of progressive loss of beta cell function,
the majority of patients with diabetes will require insulin
therapy to achieve glycemic control. Early initiation of
multiple daily insulin injections allowed rapid achievement
of glucose control and improvement in beta cell function
[20]. This eﬀect was sustained for up to two years after
discontinuation of insulin [21]. Early intensive glucose
controlhadbeenrepeatedlyshowntoimprovemicrovascular
outcomes, however, at the expense of signiﬁcant weight gain
andhypoglycemia[6].Weightgainfrominsulinuseisrelated
to its eﬀect to increase body fat and lean mass through
reductions in glycosuria, anabolic eﬀects on adipose tissue,
as well as to appetite-enhancing eﬀects [22]. However, the
type of basal insulin used may have diﬀerent eﬀects on
weight. Rosenstock et al. compared the eﬃcacy of insulin
analogs detemir and glargine when added to oral glucose-
lowering agents in insulin-na¨ ıve type 2diabetes subjects with
baseline HbA1c of 8.6% in a 52-week, open-label treat-to-
target trial [23]. Treatment with insulin detemir (n = 291)
and glargine (n = 291) resulted in a comparable decrease
in HbA1c from 8.6 to 7.2 and 7.1%, respectively. However,
there were modest reductions in weight gain seen with
determir versus glargine (+3.0kgversus+3.9kg,P = .01).
Holman et al. conducted an open-label multicenter trial to
evaluate the eﬃcacy of basal insulin, prandial insulin, and
biphasic insulin in type 2 diabetes patients inadequately
controlled (mean HbA1∼8.5%) on oral hypoglycemic agents
[24]. Patients randomized to prandial insulin (n = 239) had
a greater weight gain of 6.4 ± 0.5kg compared with patients
onbiphasicinsulin(n = 235)withweightgainof5.7 ±0.5kg
andbasal insulin (n=234) of 3.6 ±0.5kg. Clearly, theweight
gain associated with insulin is a major drawback for treating
diabetes. Further studies examining the eﬀects of antiobesity
drugs and GLP-1 agonists to combat insulin-induced weight
gain are needed.4 Journal of Obesity
3.AntidiabetesAgents that Are
WeightNeutral or Weight Reducing
3.1. Metformin. Metformin is an insulin sensitizing agent
that serves as the ﬁrst line agent in treatment of type 2
diabetes and acts by decreasing hepatic glucose production
and enhances peripheral tissue sensitivity to insulin. It
has been shown to signiﬁcantly delay the progression of
impaired glucose tolerance to diabetes in the Diabetes
Prevention Program (DPP) Study. This study was conducted
to evaluate metformin in the prevention or delaying of
the progression of type 2 diabetes in high-risk patients
[5]. Patients who had impaired fasting glucose or impaired
glucose tolerance test, were overweight and had a sedentary
lifestyle were randomized to receive metformin 850mg twice
daily (n =1,073), lifestyle-modiﬁcation (goal of 7% weight
loss and 150 minutes of physical activity per week) program
(n = 1,079), or placebo (n =1,082) with a mean followup of
2.8 years. There was a 58% reduction in incidence of diabetes
in the lifestyle-intervention group and 31% reduction in
the metformin group. Patients in the metformin group
had a greater weight loss of 2.1kg compared to placebo
but less compared with the lifestyle-intervention group of
5.6kg.
Monotherapy with metformin reduced the HbA1c up to
1.5% [25]. DeFronzo et al. conducted a two-parallel-group,
double-blind study to determine the eﬃcacy of metformin
in moderately obese patients with diabetes uncontrolled
with diet or diet plus glyburide. In the ﬁrst protocol (n =
289), patients (mean HbA1c ∼8.3) were randomized to
metformin (n = 143) or placebo (n = 146) after an eight-
week hypocaloric dietary phase. The addition of metformin
resulted in the reduction of HbA1c by 1.4% versus 0.4%
in the placebo group at 29 weeks. The metformin group
experienced weight loss of 0.6kg whereas the placebo group
had a weight reduction of 1.1kg (P = NS). In the second
protocol (n = 632), the patients (mean HbA1c ∼8.7%)
were started or continued on glyburide for ﬁve weeks. They
were then randomized to glyburide (n = 209), metformin
(n = 210), and metformin-glyburide (n = 213). Patients
given metformin-glyburide achieved a greater reduction in
HbA1c of 1.7% compared with 0.4% with metformin alone.
There was a weight loss of 3.8kg in the metformin group
compared with a weight gain of 0.4kg in the metformin-
glyburide group.
In a double-blind, open-label study, metformin-
glibenclamide combination was compared with metformin-
rosiglitazone in 318 type 2 diabetes patients uncontrolled
on metformin monotherapy (mean HbA1c ∼8.5%) [26].
Patients randomized to metformin-glibenclamide (n = 160)
had a greater reduction in Hba1c of 1.5% compared with
metformin-rosiglitazone (n=158) with a reduction in
Hba1c of 1.1% at 24 weeks. There was a greater weight gain
with the metformin-glibenclamide group compared with
the metformin-rosiglitazone group (+3.0kg versus +1.4kg).
There is a general consensus that metformin is the treatment
of choice in obese type 2 diabetes patients as it has been
shown to be either weight neutral or even result in modest
weight loss. However, combination with SUs or TZDs may
result in weight gain whereas the combination with GLP-1
analogs may enhance weight loss.
3.2. Amylin Analogs. Pramlintide is an injectable synthetic
analog of amylin which is a naturally occurring neuroen-
docrine hormone co-secreted with insulin by pancreatic beta
cells in response to food intake. Pramlintide slows gastric
emptying [27], attenuates postprandial glucagon secretion
[28], enhances satiety, and reduces food intake [29]. In
a 52-week, double-blind, multicenter trial, 656 patients
(mean HbA1c ∼9.1%) were randomized to subcutaneous
injections of either placebo or pramlintide (60μgT I D ,9 0μg
BID, or 120μg BID) in addition to their existing insulin
regimen (alone or in combination with sulfonylureas and/or
metformin) [30]. Treatment with pramlintide 120μgB I D
produced a signiﬁcant reduction in HbA1c of 0.68% at week
26 which was sustained at week 52. This eﬀect was accompa-
nied by a mean weight loss of 1.4kg compared with a weight
gain of 0.7kg in the placebo group (P<. 05). The addition
of mealtime pramlintide 120μg( n = 57) was compared with
rapid-acting insulin analogs (n = 56) in addition to basal
insulin in patients with inadequately controlled type 2 DM
(n = 113; mean HbA1c ∼ 8.2%) in a 24-week, randomized,
open-label parallel-group, multicenter study [31]. Mealtime
pramlintide and rapid-acting insulin analog (RAIA) resulted
in a reduction of Hba1c of 1.1% versus 1.3%(P = .46),
respectively. Pramlintide was weight neutral whereas RAIA
use was associated with a weight gain of 4.7±0.7kg.
The eﬃcacy of pramlintide was evaluated in obese, non-
diabetic subjects in a double-blind, placebo-controlled dose-
ranging study [32]. Four hundred and eleven obese subjects
(BMI ∼37.5) were randomized to receive pramlintide (120,
240, and 360μg BID and TID) or placebo. Pramlintide at
doses of 120μg TID and 360μg BID achieved weight loss of
3.2 ± 1.2 and 3.3 ± 1.1kg, respectively, at 4 months. After
completion of the 4-month study, 260 subjects continued to
participate in the single-blind extension for 8 months. There
was a progressive reduction in weight of 6.1 ± 2.1 and 7.2 ±
2.3kg, respectively, at 12 months. In addition, 40 and 43%
of patients treated with pramlintide 120μg BID and 360μg
TID compared with 12% of patients in the placebo group
achieved a reduction of >10% of baseline weight. These data
are encouraging in that weight control is possible with the
use of amylin analogs in patients inadequately controlled on
insulin therapy.
3.3. Glucagon-Like Peptide-1 (GLP-1) Analogs. GLP-1 ana-
logs (exenatide and ligraglutide) are the latest medications
used to treat diabetes and have favorable eﬀects on both
glycemic and weight control. In diabetes and obesity, the
GLP-1 response to an oral glucose load is blunted con-
tributing toward impaired insulin secretion and prandial
hyperglycemia [33]. GLP-1 enhances insulin secretion in a
glucose-dependent manner, accounting for about 50–70%
of the insulin secreted in response to oral glucose [34], and
suppresses glucagon secretion [35]. Weight loss from GLP-
1 analogs results from the eﬀects of hormone to promote
satiety and slow gastric emptying [36, 37]. Further, animal
studies have shown beneﬁcial eﬀect of GLP-1 hormone onJournal of Obesity 5
beta cell proliferation and inhibiting apoptosis [38]. These
eﬀects are of particular signiﬁcance given that beta-cell
failure occurs prior to the onset of diabetes.
Exenatide has a 53% homology to human GLP-1. It
is available subcutaneously and due to a short half-life of
2–4 hours, it is administered twice daily and at least 60
minutes before meals. In a 30-week triple-blind, placebo-
controlled trial, 336 patients inadequately controlled on
maximum doses of metformin (mean HbA1c ∼8.2%) were
randomized to receive 5μg exenatide or placebo twice daily
for 4 weeks followed by 5 or 10μg exenatide or placebo twice
daily for 26 weeks [39]. Exenatide 5μga n d1 0 μgr e s u l t e d
in a signiﬁcant reduction in HbA1c (−0.40% and −0.78%,
resp.) compared with placebo (+0.085%). Moreover, there
was a dose-dependent reduction in body weight. Patients
on exenatide 10μg had a weight loss of 2.8kg compared
with 1.6kg on exenatide 5μg. In an uncontrolled open-label
extension of the prior 30-week study, 150 patients opted to
continue exenatide treatment for another 52 weeks for a total
of 82 weeks [40]. Exenatide was associated with a reduction
in HbA1c of 1.0 ± 0.1% and with weight loss of 3.0 ± 0.6kg
at30weeks,eﬀectsweresustainedattheendof82weekswith
a ﬁnal HbA1c reduction of 1.3 ± 0.1% and weight loss of 5.3
± 0.8kg.
The long-term eﬃcacy of exenatide was assessed in
an open-ended, open-label clinical trial in which patients
from three placebo-controlled trials and their open-label
extensions were enrolled for 3 years. A total of 217 patients
completed the study [41]. The reduction in HbA1c from
baseline to week 12 (−1.1 ± 0.1%) was sustained up to 3
years (−1.0 ± 0.1%). There was progressive reduction in
body weight from baseline (−5.3 ± 0.4kg at 3 years from
−1.6 ± 0.2kg at week 12). In addition to weight reduction,
there was also a reduction in total body fat mass and truncal
fat mass compared to the use of glargine [42]. The use of
exenatide (10μg BID with a 4-week 5μg dose initiation) in
addition to decreased calorie intake in nondiabetic obese
subjects(n = 152)resultedinweightlossof5.1 ±0.5kgfrom
baseline versus 1.6 ± 0.5kg with placebo at the end of a 24-
week randomized study [43].
L i r a g l u t i d ei sm o r er e c e n t l ya p p r o v e db yF D A( J a n u a r y
2010) to be used as a once-daily subcutaneous injection
for type 2 diabetes. In contrast to exenatide, liraglutide
has a 97% homology to native human GLP-1 and has a
longer half-life of 13 hours due to the presence of a fatty
moiety allowing it to bind to albumin rendering it resistant
to degradation by the DPP-4 enzyme [44]. Garber et al.
conducted a 52-week double-blind, double-dummy, active-
control, parallel-group study wherein 746 patients with early
type 2 diabetes (mean HbA1c 8.2%) were randomized to
once-daily subcutaneous liraglutide (1.2mg or 1.8mg) or
oral glimepiride 8mg [45]. Liraglutides 1.2mg and 1.8mg
were associated with a reduction in HbA1c of 0.84% and
1.14%, respectively, compared with 0.51% with glimepiride.
There was a dose-dependent reduction in body weight with
1.2 and 1.8mg liraglutides (−1.85kg and −2.26kg, resp.).
The addition of liraglutide with metformin and TZDs
was studied in a 26-week, double-blind, placebo-controlled
trial. Subjects (n = 533) were randomized to once-daily
liraglutide (1.2mg or 1.8mg) or placebo in addition to
metformin (1g BID) and rosiglitazone (4mg BID) [46].
The addition of liraglutide resulted in a mean reduction
of HbA1c of 1.5% for both the 1.2 and 1.8mg liraglutide
doses with a dose-dependent weight loss of 1-2kg. In
a 26-week, multinational, parallel-group trial, liraglutide
was compared to glargine in addition to metformin and
sulfonylurea [47]. Five-hundred-eighty-one patients were
randomized (2:1:2) to liraglutide 1.8mg (n=232), placebo
(n=115), and open-label insulin glargine (n = 234) in
addition to metformin (1g BID) and glimepiride (4mg
once daily). There was a greater reduction in HbA1c with
liraglutide compared with insulin glargine (−1.33% versus
−1.09%). Liraglutide 1.8mg resulted in a mean weight loss
of 1.8kg from baseline compared with 0.42kg in the placebo
group.Patientsoninsulinglarginegained1.6kg.Inaddition,
waist circumference decreased signiﬁcantly in the liraglutide
group (−1.50cm) whereas patients on insulin glargine had
an increase in waist circumference (+0.89cm).
Buse et al. compared the eﬃcacy of liraglutide 1.8mg
once daily with exenatide 10μg twice daily in a 26-week
open-label, parallel-group multinational study [48]. Patients
(n = 464) randomized to liraglutide (n = 233) had
a greater reduction in HbA1c than to exenatide (−1.12%
versus −0.79%, resp.) and more patients achieved HbA1c
value of <7% with the liraglutide group (54% versus 43%).
Both groups achieved weight loss (−3.24kg versus −2.87kg;
P = NS). The eﬃcacy of liraglutide (1.2mg, 1.8mg, 2.4mg,
or 3.0mg) was assessed in obese nondiabetic individuals
in a 20-week double-blind, placebo-controlled trial with
an open-label orlistat comparator [49]. Individuals in the
liraglutide group signiﬁcantly lost more weight compared to
placebo at all doses (P<. 003) and orlistat group (P = .003
for liraglutide 2.4mg and P<. 001 for liraglutide 3mg).
Mean weight loss with liraglutide at diﬀerent doses ranged
from an average of 4.8–7.2kg compared with 2.8kg with
placebo and 4.1kg with orlistat. About 76% of individuals
(n = 70) on liraglutide 3.0mg lost >5% of their weight
compared with 30%(n = 29) with placebo or 44%(n =
42) with orlistat. Liraglutide decreased the prevalence of
prediabetes (impaired fasting glucose or impaired glucose
tolerance) by 84–96% with 1.8 to 3mg per day.
3.4. Dipeptidyl-Peptidase- (DPP-) 4 Inhibitors. Sitagliptin,
saxagliptin,andvildagliptinareDPP-4inhibitorsthatinhibit
the degradation of endogenous GLP-1. These are available as
oral agents. Sitagliptin and saxagliptin are FDA approved for
monotherapy and use with metformin for type 2 diabetes.
Vildagliptin is approved for use in Europe. Aschner et al.
evaluated the eﬃcacy of sitagliptin as monotherapy in type 2
diabetes patients in a double-blind, placebo-controlled study
[50]. A total of 741 patients with baseline HbA1c 8.0% were
randomized to sitagliptin 100mg or 200mg once daily or
placebo for 24 weeks. Sitagliptin at doses of 100 or 200mg
had a signiﬁcant reduction in HbA1c of 0.69 and 0.94%,
respectively, with no signiﬁcant change in body weight.
In another double-blind, placebo-controlled, parallel-
group study in which 1091 patients with type 2 dia-
betes (mean HbA1c 8.8%) were randomized to sitaglipin6 Journal of Obesity
100mg/metformin1000mg(S100/M1000group),sitagliptin
100mg/metformin 2000mg (S100/M2000 group), met-
formin 1000mg (M1000 group), metformin 2000mg
(M2000 group), sitagliptin 100mg (S100 group), or placebo
[51]. All treatment groups achieved a statistically signiﬁcant
reduction in HbA1c from baseline compared with placebo
and respective monotherapies at 24 weeks (P<. 001).
Patients in the S100/M2000 group had a reduction in Hba1c
of 2.07%, S100/M1000 group with a reduction of 1.57%,
M2000 group with a reduction of 1.30%, M1000 group with
a reduction of 0.99%, and S100 group with reduction of
0.83%. There were signiﬁcant reductions in body weight
from baseline (−0 . 6t o1 . 3 k g )i na l lg r o u p s ,e x c e p ti nt h e
sitagliptin group with no change in weight. Thus, as opposed
to using SUs with metformin that may promote weight gain
andruntheriskofhypoglycemia,theuseofDPP-4inhibitors
with metformin would be expected to result in less weight
gain without the risk of hypoglycemia.
Similar to the eﬀects of sitagliptin, saxagliptin at doses of
2.4, 5, and 10mg, in addition to metformin, also similarly
produced a signiﬁcant reduction in HbA1c from baseline
(−0.59 to 0.69%) with no signiﬁcant change in weight [52].
4. Use of AntiobesityAgents inType2 DM
At present, there are only two antiobesity agents approved
for long-term use by the FDA. These agents may be used
with lifestyle modiﬁcation and metformin. Orlistat and
sibutraminehavebeenstudiedintype2diabetespopulations
which will be brieﬂy reviewed here.
4.1. Orlistat (Xenical). Orlistat is a lipase inhibitor that
inhibits the absorption of dietary fat in the gastrointestinal
tract by approximately 30% at dosage of 120mg three times
daily in combination with a mildly hypocaloric diet [53].
Xenical in the Prevention of Diabetes in Obese Subjects
(XENDOS) Study, a 4-year double-blind, prospective study,
wasconductedtodeterminethelong-termeﬀectoforlistatin
reducing progression to type 2 diabetes [54]. Obese patients
(n =3,305; BMI ∼37kg/m2)w i t hn o r m a l( 7 9 % )o ri m p a i r e d
(21%)glucosetolerancewererandomizedtolifestylechanges
plus either orlistat 120mg or placebo, three times daily.
Patients treated with orlistat achieved signiﬁcantly greater
weight loss (5.8kg) compared to placebo (3.0kg). More
patients in the orlistat group achieved a weight loss of ≥10%
compared to the placebo group (26% versus 15.6%). There
was also a greater reduction in incidence of type 2 diabetes
with the orlistat group versus the control group of 6.2%
versus 9.0% corresponding to a risk reduction of 37.3%.
Several studies were also conducted to determine the
eﬀect of orlistat in patients with type 2 DM. Jacob et al.
conducted a multicenter double-blind, placebo-controlled
study in which overweight or obese patients with type 2
diabetes (mean HbA1c ∼8.5%; BMI ∼37kg/m2) on either
metformin, sulfonylurea, and/or insulin were randomized
to treatment with orlistat 120mg three times daily (n =
1279) or placebo (n = 1271) [55]. Patients treated with
orlistat had a statistically signiﬁcant greater decrease in body
weight(−3.8kg)thanplacebo-treatedpatients(−1.4kg)and
a larger decrease in HbA1c compared with placebo (−0.74%
versus −0.31%). In addition, patients with minimal weight
loss (<1% of baseline body weight) were also found to
have a signiﬁcant improvement in glycemic control with
orlistat (HbA1c −0.29%) compared with placebo (±0.14%)
suggesting that improvement of glycemic control associated
with orlistat may be independent of weight loss. The greater
reduction in weight loss and improvement in glycemic
control with orlistat has also been shown consistently in
combination with metformin and sulfonylureas [56, 57]
or insulin [58] in individual studies. In a 52-week, ran-
domized, double-blind placebo-controlled study in which
type 2 diabetes patients (n = 220) treated with metformin
alone or in combination with sulfonylurea were randomized
to orlistat versus placebo [56]. Orlistat-treated patients
achieved greater reduction in weight (5%) versus placebo
(1.8%) as well as greater reduction in HbA1c (−1.1%
versus −0.2%). These were also accompanied by greater
improvements in beta cell function and insulin resistance.
Thus, treatment with orlistat may counteract the weight
gain eﬀects associated with SUs and insulin and is currently
available over the counter.
4.2. Sibutramine. Sibutramine is a serotonin-norepineph-
rine reuptake inhibitor. It acts by decreasing food intake
by reducing appetite and increasing satiety [59]. In a mul-
ticenter, double-blind, placebo-controlled study, 348 obese
patients (BMI∼35kg/m2) were randomized to sibutramine
15mg daily or placebo [60]. The sibutramine-treated group
had greater weight loss compared to placebo (8.1kg versus
5.1kg). More patients on the sibutramine group lost more
than 5% (62% versus 41%) and 10% (40% versus 19%) of
theirbaselineweightcomparedtoplacebo.Aronneetal.con-
ducted a study to evaluate the eﬀects of coadministration of
pramlintide with sibutramine or phentermine in a 25-week
multicenter trial [61]. Overweight or obese, nondiabetic
subjects (n = 244) were randomized to pramlintide (120μg
TID), pramlintide (120μg TID) + oral sibutramine (10mg
once daily), or pramlintide (120μg TID) + phentermine
(37.5mg once daily). Subjects who received combination
treatment achieved greater weight loss (−11.3kg) compared
with pramlintide alone (−3.6kg) or placebo (−2.1kg).
McNulty et al. conducted a 12-month, prospective,
double-blindstudyinwhich195subjectswithtype2diabetes
(mean HbA1c ∼ 9.5%; BMI ∼ 36kg/m2)t r e a t e dw i t h
metformin were randomized to sibutramine 15 or 20mg
daily or placebo [62]. There was signiﬁcant weight loss in
the sibutramine group with both 15mg (−5.5 ± 0.6kg) and
20mg (−8.0 ± 0.9kg) doses compared to placebo (−0.2 ±
0.5kg) with no signiﬁcant change in HbA1c. However, in
subjects who lost more than 10% of their body weight, there
was a signiﬁcant decrease in HbA1c averaging 1.2%. Gokcel
et al. evaluated the eﬃcacy of sibutramine in combination
with oral hypoglycemic agents in obese patients with poorly
controlled type 2 diabetes (mean HbA1c ∼9.9%; BMI ∼
38kg/m2)[ 63]. Sixty patients were randomized to sibu-
tramine 10mg twice daily or placebo. Sibutramine induced
ag r e a t e rm e a nr e d u c t i o ni nw e i g h tt h a np l a c e b o( −9.61kg
versus −0.91kg). HbA1c reduced signiﬁcantly at 6 monthsJournal of Obesity 7
by 2.73% in the sibutramine group compared with 0.53%
in the placebo group. A recent randomized control trial
of sibutramine compared with placebo on cardiovascular
eﬀects in obese patients has shown an increase in risk for
myocardial infarction, however this increase wasn’t noted in
patients with diabetes [64]. Careful consideration for risk
versus beneﬁt is needed for the use of sibutramine for weight
loss in diabetes.
4.3. Summary. In recent years, an increasing number of
antidiabetes agents, which have varying eﬀects on glycemic
control and weight, have become available. The treatment
of diabetes should not only focus on glycemic control as
its sole intention, but it should factor in the eﬀect of these
various agents on weight as well, since obesity aggravates
insulin resistance, beta cell failure, and cardiovascular risk.
SUs, TZDs, and insulin, when used alone or in combination,
are usually associated with modest weight gain, whereas
metformin and amylin analogues are weight neutral or result
in weight loss. DPP-4 inhibitors are weight neutral whereas
GLP-1 analogues are associated with weight loss. Therefore,
in contrast to the conventional glycemic control strategy that
results in signiﬁcant weight gain, we propose that aggressive
weightlosswithlifestylemodiﬁcationandmetforminremain
the foremost strategy followed by the use of incretin analogs.
If glycemic control remains inadequate, the addition of low-
dose TZDs would be a reasonable approach followed by
the addition of basal insulin as necessary. Alternatively, the
use of antiobesity agents such as orlistat, phentermine, or
sibutramine has been shown to prevent or delay the onset
of type 2 diabetes in obese patients and minimize the weight
gain associated with SUs and insulin. These strategies should
help balance glycemic and weight control in patients with
obesity and diabetes.
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